IP Library Patent Application 16877352
Patent Application
App. No. 16/877,352

ANTIBODIES AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/877,352
Abstract

Disclosed herein are methods and compositions for targeting a complex comprising a neoantigen presenting protein and a neoantigen in cancer. Further disclosed herein are antibodies that selectively bind to a complex comprising a neoantigen presenting protein and a neoantigen, as well as methods of use thereof.

Claims (9)

1 . A method of treating a cancer characterized by the presence of a plurality of antigen processing machinery (APM)-proficient cancer cells that differentially expresses a neoantigen presenting protein and a neoantigen, the method comprising contacting the cancer cells with an antibody that selectively binds to both the neoantigen presenting protein and the neoantigen in a complex comprising the neoantigen presenting protein and the neoantigen, thereby treating the cancer.

2 . The method of claim 1 , wherein the antibody does not have a binding affinity to (i) the neoantigen presenting protein alone; or (ii) the neoantigen alone.

3 . The method of claim 1 , wherein the neoantigen comprises, consists essentially of, or consists of a sequence according to SEQ ID NO: 3 (VMAPRTLFL), SEQ ID NO: 13 (VMAPRTLIL), SEQ ID NO: 14 (VMPPRTLLL), or SEQ ID NO: 31 (VMAPRTLVL).

4 . The method of claim 1 , wherein the antibody is a camelid single domain antibody.

5 . The method of claim 1 , wherein the antibody is a multispecific antibody.

6 . The method of claim 1 , wherein the antibody is a multifunctional antibody.

7 . The method of claim 1 , wherein the binding of the antibody to the complex induces an immune response against the cancer cell.

8 . The method of claim 1 , wherein the antibody further comprises a conjugated therapeutic moiety.

9 . The method of claim 8 , wherein the therapeutic moiety kills the cancer cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2022
From: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 061615/0332 →
MERGER Recorded Jan 6, 2022
From: ABEXXA BIOLOGICS, INC.
To: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Reel/Frame 058584/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: WEIDANZ, JON
To: ABEXXA BIOLOGICS, INC.
Reel/Frame 053846/0249 →